64576 Federal Register / Vol. 69, No. 214 / Friday, November 5, 2004 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

Notice of Grant Award to Waimanalo 

Health Center for a Project Entitled, 

‘‘The Hauula Community Diabetes 

Screening Program’’

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS.

ACTION: Notice of grant award.

SUMMARY: The Centers for Medicare & 

Medicaid Services has awarded a grant 

entitled ‘‘The Hauula Community 

Diabetes Screening Program’’ to the 

Waimanalo Health Center, 41–1347 

Kalanianaole Highway, Waimanalo, 

Hawaii 96795, in response to an 

unsolicited application. 

Purpose: The Waimanalo Health 

Center proposes to provide diabetes and 

related risk factor health screening as 

well as relevant health educational and 

behavioral intervention services to the 

geographically isolated, mostly-Samoan 

community of Hauula (pop. 3,651) on 

Oahu. Services will be targeted to its 

Samoan citizens but open to all 

residents of Hauula regardless of their 

ethnicity. 

Total Amount of Award: $987,317. 

Project Period: September 30, 2004, 

through March 30, 2006. 

Sole Source Justification: This 

unsolicited proposal is responsive to the 

Senate Appropriations Committee’s 

commitment to the concept of a 

demonstration project for American 

Samoans in Hawaii that will integrate 

social services, to include traditional 

health, preventive health, prevention 

and disease management, and address 

the health disparities among Native 

Hawaiians and other minority 

populations by utilizing the expertise of 

the Waimanalo Health Center. The grant 

will provide diabetes and related risk 

factor health screening, as well as 

relevant health educational and 

behavioral intervention services, to the 

geographically isolated, mostly-Samoan 

community of Hauula on Oahu, but 

project services will be made available 

to all Hauula residents regardless of 

their ethnicity. These services will help 

improve the administration and 

effectiveness of programs carried on or 

assisted under the Social Security Act 

and programs related thereto. The 

appropriation to the CMS research 

budget was increased to include funding 

to carry out this project.

FOR FURTHER INFORMATION CONTACT:

Mary Kapp, Project Officer, Division of 

Beneficiary Research; Research and 

Evaluation Group; Office of Research 

Development, and Information, C3–19–

07, 7500 Security Boulevard, Baltimore, 

MD 21244, (410) 786–0360, or Judith 

Norris, Grants Officer, OICS/AGG/CMS, 

C2–21–15, 7500 Security Boulevard, 

Baltimore, MD 21244, (410) 786–5130.

Authority: (Catalog of Federal Domestic 

Assistance Program No. 93.779 (CMS) 

Research, Demonstrations and Evaluations) 

Section 1110 of the Social Security Act.

Dated: October 29, 2004. 

Mark B. McClellan, 

Administrator, Centers for Medicare & 

Medicaid Services.

[FR Doc. 04–24765 Filed 11–4–04; 8:45 am] 

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories Which 

Meet Minimum Standards To Engage in 

Urine Drug Testing for Federal 

Agencies

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories currently 

certified to meet the standards of 

Subpart C of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908), 

on September 30, 1997 (62 FR 51118), 

and on April 13, 2004 (69 FR 19644). 

A notice listing all currently certified 

laboratories is published in the Federal 

Register during the first week of each 

month. If any laboratory’s certification 

is suspended or revoked, the laboratory 

will be omitted from subsequent lists 

until such time as it is restored to full 

certification under the Mandatory 

Guidelines. 

If any laboratory has withdrawn from 

the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end, 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http://workplace.samhsa.gov

and http://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh or Dr. Walter Vogl, 

Division of Workplace Programs, 

SAMHSA/CSAP, Room 2–1035, 1 Choke 

Cherry Road, Rockville, Maryland 

20857; (240) 276–2600 (voice), (240) 

276–2610 (fax).

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were developed 

in accordance with Executive Order 

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Mandatory 

Guidelines, ‘‘Certification of 

Laboratories Engaged in Urine Drug 

Testing for Federal Agencies,’’ sets strict 

standards that laboratories must meet in 

order to conduct drug and specimen 

validity tests on urine specimens for 

Federal agencies. To become certified, 

an applicant laboratory must undergo 

three rounds of performance testing plus 

an on-site inspection. To maintain that 

certification, a laboratory must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories which claim to be in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A laboratory 

must have its letter of certification from 

HHS/SAMHSA (formerly: HHS/NIDA) 

which attests that it has met minimum 

standards. 

In accordance with Subpart C of the 

Mandatory Guidelines dated April 13, 

2004 (69 FR 19644), the following 

laboratories meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens:

ACL Laboratories, 8901 W. Lincoln Ave., 

West Allis, WI 53227, (414) 328–7840/

(800) 877–7016, (Formerly: Bayshore 

Clinical Laboratory). 

ACM Medical Laboratory, Inc., 160 Elmgrove 

Park, Rochester, NY 14624, (585) 429–

2264. 

Advanced Toxicology Network, 3560 Air 

Center Cove, Suite 101, Memphis, TN 

38118, (901) 794–5770/(888) 290–1150. 

Aegis Analytical Laboratories, Inc., 345 Hill 

Ave., Nashville, TN 37210, (615) 255–2400. 

Baptist Medical Center—Toxicology 

Laboratory, 9601 I–630, Exit 7, Little Rock, 

AR 72205–7299, (501) 202–2783, 

(Formerly: Forensic Toxicology Laboratory 

Baptist Medical Center). 

Clinical Reference Lab, 8433 Quivira Rd., 

Lenexa, KS 66215–2802, (800) 445–6917. 

Diagnostic Services Inc., dba DSI, 12700 

Westlinks Dr., Fort Myers, FL 33913, (239) 

561–8200/(800) 735–5416. 

Doctors Laboratory, Inc., 2906 Julia Drive, 

Valdosta, GA 31602, (229) 671–2281. 

DrugProof, Division of Dynacare/Laboratory 

of Pathology, LLC, 1229 Madison St., Suite 

500, Nordstrom Medical Tower, Seattle, 

WA 98104, (206) 386–2661/(800) 898–

0180, (Formerly: Laboratory of Pathology of 

Seattle, Inc., DrugProof, Division of 

Laboratory of Pathology of Seattle, Inc.). 

DrugScan, Inc., P.O. Box 2969, 1119 Mearns 

Rd., Warminster, PA 18974, (215) 674–

9310. 

Federal Register / Vol. 69, No. 214 / Friday, November 5, 2004 / Notices 64577

* The Standards Council of Canada (SCC) voted 

to end its Laboratory Accreditation Program for 

Substance Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that program were 

accredited to conduct forensic urine drug testing as 

required by U.S. Department of Transportation 

(DOT) regulations. As of that date, the certification 

of those accredited Canadian laboratories will 

continue under DOT authority. The responsibility 

for conducting quarterly performance testing plus 

periodic on-site inspections of those LAPSAaccredited laboratories was transferred to the U.S. 

HHS, with the HHS’ NLCP contractor continuing to 

have an active role in the performance testing and 

laboratory inspection processes. Other Canadian 

laboratories wishing to be considered for the NLCP 

may apply directly to the NLCP contractor just as 

U.S. laboratories do. 

Upon finding a Canadian laboratory to be 

qualified, HHS will recommend that DOT certify 

the laboratory (Federal Register, July 16, 1996) as 

meeting the minimum standards of the Mandatory 

Guidelines published in the Federal Register on 

April 13, 2004 (69 FR 19644). After receiving DOT 

certification, the laboratory will be included in the 

monthly list of HHS certified laboratories and 

participate in the NLCP certification maintenance 

program.

Dynacare Kasper Medical Laboratories*, 

10150–102 St., Suite 200, Edmonton, 

Alberta, Canada T5J 5E2, (780) 451–3702/

(800) 661–9876.

ElSohly Laboratories, Inc., 5 Industrial Park 

Dr., Oxford, MS 38655, (662) 236–2609. 

Express Analytical Labs, 3405 7th Ave., Suite 

106, Marion, IA 52302, (319) 377–0500. 

General Medical Laboratories, 36 South 

Brooks St., Madison, WI 53715, (608) 267–

6225. 

Kroll Laboratory Specialists, Inc., 1111 

Newton St., Gretna, LA 70053, (504) 361–

8989/(800) 433–3823 (Formerly: Laboratory 

Specialists, Inc.). 

LabOne, Inc., 10101 Renner Blvd., Lenexa, 

KS 66219, (913) 888–3927/(800) 873–8845 

(Formerly: Center for Laboratory Services, 

a Division of LabOne, Inc.). 

LabOne, Inc., d/b/a Northwest Toxicology, 

1141 E. 3900 S., Salt Lake City, UT 84124, 

(801) 293–2300/(800) 322–3361 (Formerly: 

NWT Drug Testing, NorthWest Toxicology, 

Inc.; Northwest Drug Testing, a division of 

NWT Inc.). 

Laboratory Corporation of America Holdings, 

7207 N. Gessner Rd., Houston, TX 77040, 

(713) 856–8288/(800) 800–2387. 

Laboratory Corporation of America Holdings, 

69 First Ave., Raritan, NJ 08869, (908) 526–

2400/(800) 437–4986, (Formerly: Roche 

Biomedical Laboratories, Inc.). 

Laboratory Corporation of America Holdings, 

1904 Alexander Dr., Research Triangle 

Park, NC 27709, (919) 572–6900/(800) 833–

3984 (Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of Roche 

Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A Member 

of the Roche Group). 

Laboratory Corporation of America Holdings, 

10788 Roselle St., San Diego, CA 92121, 

(800) 882–7272 (Formerly: Poisonlab, Inc.). 

Laboratory Corporation of America Holdings, 

1120 Stateline Rd. West, Southaven, MS 

38671, (866) 827–8042/(800) 233–6339 

(Formerly: LabCorp Occupational Testing 

Services, Inc.; MedExpress/National 

Laboratory Center). 

Marshfield Laboratories, Forensic Toxicology 

Laboratory, 1000 North Oak Ave., 

Marshfield, WI 54449, (715) 389–3734/

(800) 331–3734. 

MAXXAM Analytics Inc.*, 6740 Campobello 

Road, Mississauga, ON, Canada L5N 2L8, 

(905) 817–5700 (Formerly: NOVAMANN 

(Ontario) Inc.). 

MedTox Laboratories, Inc., 402 W. County 

Rd. D, St. Paul, MN 55112, (651) 636–7466/

(800) 832–3244. 

MetroLab-Legacy Laboratory Services, 1225 

NE 2nd Ave., Portland, OR 97232, (503) 

413–5295/(800) 950–5295. 

Minneapolis Veterans Affairs Medical Center, 

Forensic Toxicology Laboratory, 1 Veterans 

Dr., Minneapolis, MN 55417, (612) 725–

2088. 

National Toxicology Laboratories, Inc., 1100 

California Ave., Bakersfield, CA 93304, 

(661) 322–4250/(800) 350–3515. 

One Source Toxicology Laboratory, Inc., 1213 

Genoa-Red Bluff, Pasadena, TX 77504, 

(888) 747–3774 (Formerly: University of 

Texas Medical Branch, Clinical Chemistry 

Division; UTMB Pathology-Toxicology 

Laboratory). 

Oregon Medical Laboratories, P.O. Box 972, 

722 East 11th Ave., Eugene, OR 97440–

0972, (541) 687–2134. 

Pacific Toxicology Laboratories, 9348 DeSoto 

Ave., Chatsworth, CA 91311, (800) 328–

6942 (Formerly: Centinela Hospital Airport 

Toxicology Laboratory). 

Pathology Associates Medical Laboratories, 

110 West Cliff Dr., Spokane, WA 99204, 

(509) 755–8991/(800) 541–7897, x7. 

Physicians Reference Laboratory, 7800 West 

110th St., Overland Park, KS 66210, (913) 

339–0372/(800) 821–3627. 

Quest Diagnostics Incorporated, 3175 

Presidential Dr., Atlanta, GA 30340, (770) 

452–1590/(800) 729–6432 (Formerly: 

SmithKline Beecham Clinical Laboratories; 

SmithKline Bio-Science Laboratories).

Quest Diagnostics Incorporated, 4770 Regent 

Blvd., Irving, TX 75063, (800) 824–6152 

(Moved from the Dallas location on 03/31/

01; Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Quest Diagnostics Incorporated, 4230 South 

Burnham Ave., Suite 250, Las Vegas, NV 

89119–5412, (702) 733–7866/(800) 433–

2750 (Formerly: Associated Pathologists 

Laboratories, Inc.). 

Quest Diagnostics Incorporated, 400 Egypt 

Rd., Norristown, PA 19403, (610) 631–

4600/(877) 642–2216 (Formerly: 

SmithKline Beecham Clinical Laboratories; 

SmithKline Bio-Science Laboratories). 

Quest Diagnostics Incorporated, 506 E. State 

Pkwy., Schaumburg, IL 60173, (800) 669–

6995/(847) 885–2010 (Formerly: 

SmithKline Beecham Clinical Laboratories; 

International Toxicology Laboratories). 

Quest Diagnostics Incorporated, 7600 Tyrone 

Ave., Van Nuys, CA 91405, (818) 989–

2520/(800) 877–2520 (Formerly: 

SmithKline Beecham Clinical 

Laboratories). 

Scientific Testing Laboratories, Inc., 450 

Southlake Blvd., Richmond, VA 23236, 

(804) 378–9130. 

Sciteck Clinical Laboratories, Inc., 317 

Rutledge Rd., Fletcher, NC 28732, (828) 

650–0409. 

S.E.D. Medical Laboratories, 5601 Office 

Blvd., Albuquerque, NM 87109, (505) 727–

6300/(800) 999–5227. 

South Bend Medical Foundation, Inc., 530 N. 

Lafayette Blvd., South Bend, IN 46601, 

(574) 234–4176, x276. 

Southwest Laboratories, 4645 E. Cotton 

Center Boulevard, Suite 177, Phoenix, AZ 

85040, (602) 438–8507/(800) 279–0027. 

Sparrow Health System, Toxicology Testing 

Center, St. Lawrence Campus, 1210 W. 

Saginaw, Lansing, MI 48915, (517) 364–

7400 (Formerly: St. Lawrence Hospital & 

Healthcare System). 

St. Anthony Hospital Toxicology Laboratory, 

1000 N. Lee St., Oklahoma City, OK 73101, 

(405) 272–7052. 

Toxicology & Drug Monitoring Laboratory, 

University of Missouri Hospital & Clinics, 

301 Business Loop 70 West, Suite 208, 

Columbia, MO 65203, (573) 882–1273. 

Toxicology Testing Service, Inc., 5426 NW. 

79th Ave., Miami, FL 33166, (305) 593–

2260. 

U.S. Army Forensic Toxicology Drug Testing 

Laboratory, 2490 Wilson St., Fort George G. 

Meade, MD 20755–5235, (301) 677–7085.

Anna Marsh, 

Executive Officer, SAMHSA.

[FR Doc. 04–24517 Filed 11–4–04; 8:45 am] 

BILLING CODE 4160–20–P

DEPARTMENT OF HOMELAND 

SECURITY 

Citizenship and Immigration Services 

[CIS No. 2336–04] 

SES Performance Review Board

AGENCY: Citizenship and Immigration 

Services, DHS.

ACTION: Notice.

SUMMARY: This notice announces the 

appointment of the members of the U.S. 

Citizenship and Immigration Services 

(USCIS) Performance Review Board 

(PRB). The purpose of the PRB is to 

review and make recommendations 

concerning proposed performance 

appraisals, ratings, bonuses, pay 

adjustments, and other appropriate 

personnel actions for incumbents of 

Senior Executive Service (SES) 

positions for which the Director, USCIS, 

is the appointing authority. The Board 

will perform PRB functions for other 

Department of Homeland Security 

(DHS) SES positions if requested.

DATES: This notice is effective 

November 5, 2004.

FOR FURTHER INFORMATION CONTACT: Ms. 

Kathleen T. Hochman, Human Capital 

Officer, USCIS, Office of 

Administration, 20 Massachusetts 

Avenue, NW., Room 1016, Washington, 

DC 20529. Telephone (202) 272–1330.

SUPPLEMENTARY INFORMATION: Title 5 

U.S.C. 4314(c) requires each federal